Tempus AI (TEM) has seen a significant surge on Wednesday, with its stock climbing 14.62% in just one day. The significant boost in TEM stock followed the announcement of a multiyear collaboration ...

In this article, we are going to take a look at where Tempus AI Inc. (NASDAQ:TEM) stands against other firms that recorded double-digit gains last week. Ten companies finished the past trading ...

Tempus AI has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven ...

AstraZeneca has started work with tech companies Tempus and Pathos AI on a project that aims to generate a wide-ranging and comprehensive generative artificial intelligence model for oncology.

Tempus AI has a 52-week low of $22.89 and a 52-week high of $91.45. Insider Transactions at Tempus AI In related news, CEO Eric P. Lefkofsky sold 3,240,234 shares of Tempus AI stock in a ...

In the last three months, 9 analysts have published ratings on Tempus AI TEM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on ...

Investing.com -- Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc. The collaborations, ...